Burney Co. Acquires 71,331 Shares of Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)

Burney Co. boosted its holdings in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) by 603.4% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 83,152 shares of the specialty pharmaceutical company’s stock after purchasing an additional 71,331 shares during the period. Burney Co.’s holdings in Supernus Pharmaceuticals were worth $3,007,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. JPMorgan Chase & Co. grew its holdings in shares of Supernus Pharmaceuticals by 40.6% in the 3rd quarter. JPMorgan Chase & Co. now owns 253,396 shares of the specialty pharmaceutical company’s stock valued at $7,901,000 after acquiring an additional 73,118 shares in the last quarter. Principal Financial Group Inc. boosted its position in Supernus Pharmaceuticals by 5.4% during the third quarter. Principal Financial Group Inc. now owns 285,411 shares of the specialty pharmaceutical company’s stock valued at $8,899,000 after purchasing an additional 14,566 shares during the last quarter. Franklin Resources Inc. grew its stake in Supernus Pharmaceuticals by 7.6% in the third quarter. Franklin Resources Inc. now owns 29,981 shares of the specialty pharmaceutical company’s stock valued at $987,000 after purchasing an additional 2,121 shares in the last quarter. Geode Capital Management LLC increased its position in shares of Supernus Pharmaceuticals by 5.3% during the 3rd quarter. Geode Capital Management LLC now owns 1,482,051 shares of the specialty pharmaceutical company’s stock worth $46,218,000 after purchasing an additional 74,438 shares during the last quarter. Finally, Barclays PLC raised its stake in shares of Supernus Pharmaceuticals by 88.3% during the 3rd quarter. Barclays PLC now owns 108,788 shares of the specialty pharmaceutical company’s stock worth $3,393,000 after purchasing an additional 51,005 shares in the last quarter.

Supernus Pharmaceuticals Trading Up 1.3 %

SUPN stock opened at $38.31 on Thursday. Supernus Pharmaceuticals, Inc. has a 1-year low of $25.53 and a 1-year high of $39.37. The business’s 50 day simple moving average is $36.61 and its 200 day simple moving average is $33.51. The firm has a market capitalization of $2.12 billion, a PE ratio of 35.80 and a beta of 0.90.

Supernus Pharmaceuticals (NASDAQ:SUPN) last released its quarterly earnings data on Monday, November 4th. The specialty pharmaceutical company reported $0.69 EPS for the quarter, beating the consensus estimate of $0.44 by $0.25. The firm had revenue of $175.70 million for the quarter, compared to the consensus estimate of $157.35 million. Supernus Pharmaceuticals had a net margin of 9.16% and a return on equity of 7.79%. The company’s quarterly revenue was up 14.2% on a year-over-year basis. During the same period in the previous year, the company earned ($0.29) earnings per share. As a group, sell-side analysts predict that Supernus Pharmaceuticals, Inc. will post 2.37 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts recently weighed in on SUPN shares. Cowen restated a “buy” rating on shares of Supernus Pharmaceuticals in a report on Friday, October 18th. Cantor Fitzgerald initiated coverage on shares of Supernus Pharmaceuticals in a research report on Monday, January 6th. They issued an “overweight” rating and a $57.00 price objective for the company. Finally, Piper Sandler reaffirmed a “neutral” rating on shares of Supernus Pharmaceuticals in a report on Friday, October 18th.

Insider Buying and Selling at Supernus Pharmaceuticals

In other Supernus Pharmaceuticals news, Director Georges Gemayel sold 14,213 shares of the company’s stock in a transaction on Thursday, November 7th. The stock was sold at an average price of $36.62, for a total value of $520,480.06. Following the transaction, the director now directly owns 13,315 shares of the company’s stock, valued at $487,595.30. This represents a 51.63 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CEO Jack A. Khattar sold 125,000 shares of Supernus Pharmaceuticals stock in a transaction on Thursday, November 7th. The stock was sold at an average price of $36.68, for a total value of $4,585,000.00. Following the sale, the chief executive officer now directly owns 926,172 shares of the company’s stock, valued at $33,971,988.96. This represents a 11.89 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 154,213 shares of company stock valued at $5,660,180 in the last three months. 9.30% of the stock is currently owned by company insiders.

Supernus Pharmaceuticals Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.